The estimated Net Worth of Vojo Vukovic is at least $996 mil dollars as of 12 December 2023. Vojo Vukovic owns over 40,000 units of Delcath Systems stock worth over $996,000 and over the last 6 years Vojo sold DCTH stock worth over $0.
Vojo has made over 3 trades of the Delcath Systems stock since 2019, according to the Form 4 filled with the SEC. Most recently Vojo bought 40,000 units of DCTH stock worth $120,000 on 12 December 2023.
The largest trade Vojo's ever made was buying 75,000 units of Delcath Systems stock on 16 August 2019 worth over $44,250. On average, Vojo trades about 17,500 units every 158 days since 2018. As of 12 December 2023 Vojo still owns at least 100,000 units of Delcath Systems stock.
You can see the complete history of Vojo Vukovic stock trades at the bottom of the page.
Vojo's mailing address filed with the SEC is C/O DELCATH SYSTEMS, INC., 566 QUEENSBURY AVENUE, QUEENSBURY, NY, 12804.
Over the last 5 years, insiders at Delcath Systems have traded over $0 worth of Delcath Systems stock and bought 1,192,084 units worth $8,856,388 . The most active insiders traders include Marco Taglietti, Gerard J Michel y Advisors, Inc. Rosalind. On average, Delcath Systems executives and independent directors trade stock every 25 days with the average trade being worth of $242,307. The most recent stock trade was executed by Gil Aharon on 19 March 2024, trading 26,882 units of DCTH stock currently worth $100,001.
Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan hydrochloride for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO includes the FOCUS clinical trial for patients with hepatic dominant ocular melanoma to investigate objective response rate in metastatic ocular melanoma; and the ALIGN trial, a Phase 3 clinical trial for intrahepatic cholangiocarcinoma. The company also provides HEPZATO as a stand-alone medical device for sale under the CHEMOSAT Hepatic Delivery System for Melphalan trade name for medical centers to treat a range of liver cancers in Europe. Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York.
Delcath Systems executives and other stock owners filed with the SEC include: